Altman Peter purchased $2K of BCDA
Altman Peter (President and CEO) purchased 2,300 shares of BioCardia, Inc. (BCDA) at an average of $0.89 ($0.85–$0.96) across 2 trades over 2026-06-17 to 2026-06-18.
How this was made
The 30-second read
Why it matters
The only new information is the insider’s open-market purchase details and the updated post-transaction share count. The text does not include any operational update, guidance, or regulatory/clinical catalyst.
Market read
Traders may note the insider buy as a small positive sentiment datapoint, but it is not a standalone fundamental catalyst in the provided text.
What to watch
The filing notes no 10b5-1 plan, but it also provides no reason for the purchase, and the price range suggests execution across two days rather than a single conviction entry.
Background
This is an SEC Form 4 insider transaction disclosure for BioCardia, Inc. (BCDA) by its President and CEO, Peter Altman.
Ticker impact
BioCardia CEO Peter Altman bought 2,300 shares in open-market trades at $0.8500 to $0.9600, per a new Form 4 filed June 22.
Near-term impact likely limited; any effect would be sentiment-driven and fade unless followed by additional fundamental news.
Form 4 confirms the transaction occurred and was newly disclosed, but the total value (~$2.0k) is modest and there is no accompanying guidance, contract, or operational update in the text.
Market effects
No sector read-through is provided beyond a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Insider buys can be routine (tax planning, liquidity needs, or pre-planned behavior) and may not signal improved fundamentals, especially at small dollar size.
Key entities
- issuerBioCardia, Inc.
Subject of the Form 4 insider transaction disclosure (BCDA).
- insiderPeter Altman
President and CEO who reported the open-market purchase of 2,300 shares.
